A step closer to a vaccine for Campylobacter jejuni, a major global cause of
diarrheal illness.
Posted: 25 March, 2026
A new vaccine candidate targeting Campylobacter jejuni, one of the leading causes of bacterial diarrhea worldwide, has shown encouraging early results in a Phase 1 trial.
The research team, led by Dr. Mario Monteiro, a professor at the University of Guelph and GlycoNet investigator, reported findings from a small randomized human trial focused on assessing safety. The vaccine was well tolerated, with mostly mild side effects, and induced antibody responses, even at low doses.
Using a glycomics-based strategy, the vaccine targets sugar (glycan) structures on the surface of C. jejuni to help the immune system recognize and respond to the bacteria.
The next step is a Phase 2 trial with a larger group of participants to determine whether the immune responses observed translate into protection against diarrheal illness.
Read more: https://news.uoguelph.ca/2026/03/vaccine-against-bacterial-diarrhea-finds-success-in-human-trials/